Press Release
July 29, 2020

Thrive Earlier Detection Completes $257 Million Series B

The Life Sciences team advised Thrive Earlier Detection Corp. on its $257 million Series B financing. The round was led by Casdin Capital and Section 32, with participation from new investors Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital, Sands Capital, funds and accounts advised by T. Rowe Price Associates, Inc., and other undisclosed investors. All of Thrive’s Series A investors returned to participate in the Series B financing.

Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.

The Goodwin team was led by Bill Collins and Kingsley Taft and included Stephanie Richards, Brittany Morreale, Josh Tarr and Rosanne Yang.

For additional details on the financing round, please read the press release and coverage in Endpoints News, FierceBiotech and Boston Business Journal.